Cerimon Pharmaceuticals Announces Creation of Scientific Advisory Board

November 3, 2006

SOUTH SAN FRANCISCO, Calif. – Cerimon Pharmaceuticals, Inc., announced today the creation of a 10-member Scientific Advisory Board (SAB). The SAB, which includes physicians, clinicians, and biotechnology industry professionals, will provide guidance and counsel on a broad range of scientific and product development issues, including clinical trial design, interpretation of clinical data, and development of regulatory strategy. Additionally, the SAB will play an important role in advising Cerimon's management team on potential new in-licensing opportunities.

“We are extremely pleased to have assembled this group of prominent scientists and industry professionals with experience in academic and commercial research and development to join the Company's inaugural SAB," stated Paul Sekhri, President and CEO of Cerimon Pharmaceuticals. "The SAB's knowledge and experience will be an integral component to the success of our clinical and regulatory programs as we move both Simulect® and topical diclofenac through U.S. clinical trials. In addition to the Company's drugs currently in development, the SAB members will provide invaluable perspectives on new product opportunities that could fill the Company's development pipeline.”

Scientific Advisory Board

Gary Patou, M.D. – Chairman of the Scientific Advisory Board, Executive V.P. and Chief Medical Officer, Cerimon Pharmaceuticals

Craig H. Bassing, Ph.D. – Assistant Professor, Department of Laboratory Medicine and Pathology; Children's Hospital of Philadelphia; University of Pennsylvania, School of Medicine; Assistant Investigator, Abramson Family Cancer Research Institute

Neri M. Cohen, M.D., Ph.D. – Chief of the Division of Thoracic Surgery, GBMC Healthcare, Greater Baltimore Medical Center

Gary S. Firestein, M.D. – Professor of Medicine and Chief of the Division of Rheumatology, Allergy & Immunology, Founding Director of the UCSD Clinical Investigation Institute, University of California San Diego

Renu Gupta, M.D. – Executive Vice President, Development and Chief Medical Officer, Transave, Inc.

Adrian C. Hayday, Ph.D. – Kay Glendinning Professor of Immunobiology and Chair of the Peter Gorer Department of Immunobiology, Guy's, King's and St Thomas' School of Medicine, King's College London

Wendye Robbins, M.D. – Chief Executive Officer, Limerick Neurosciences, Clinical Assistant Professor, Anesthesiology, Stanford University

William J. Sandborn, M.D. – Professor of Medicine at the Mayo Clinic College of Medicine, Vice Chair of the Division of Gastroenterology and Hepatology and Director of the Inflammatory Bowel Disease Interest Group at the Mayo Clinic; . Chair of the Crohn's and Colitis Foundation of America Clinical Trials Alliance

William K. Schmidt, Ph.D. – President, NorthStar Consulting, LLC, President, Eastern Pain Association

Robert D. Schreiber, Ph.D. – Alumni Endowed Professor of Pathology and Immunology, Division of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to bringing innovative therapeutics to patients with substantial, unmet medical needs. Headquartered in South San Francisco, Cerimon is engaged in the development and commercialization of therapeutic products for the specialist physician markets in autoimmune disease, inflammation, and pain. The Company employs a novel corporate strategy of in-licensing late-stage or marketed drugs to reduce the development and regulatory risk, decrease time to market, and expand the commercial potential of known drugs.

Cerimon's lead products are Simulect® (basiliximab), a monoclonal antibody, which is being advanced towards Phase 2b studies for the treatment of inflammatory bowel disease, and diclofenac, a non-steroidal anti-inflammatory drug (NSAID), which is in development for the treatment of mild to moderate chronic pain due to arthritis. In October 2005, Cerimon completed a Series A financing of $70M with MPM Capital, Nomura Phase4 Ventures, and OrbiMed Advisors.